Phio CEO buys 10,000 shares at $1.06 per share

Phio Pharmaceuticals Corp. (PHIO) reported that Chairman, President and CEO Robert J. Bitterman purchased 10,000 shares of common stock on August 18, 2026, in an open-market or private transaction at $1.06 per share.

Rhea-AI Filing Summary

Phio Pharmaceuticals Corp. (PHIO) reported that Chairman, President and CEO Robert J. Bitterman purchased 10,000 shares of common stock on August 18, 2026, in an open-market or private transaction at $1.06 per share. Following this transaction, he directly holds 431,421 shares, which include shares underlying unvested restricted stock units.

Insider Trade Summary

Net Buyer: 10,000 shares

Net Buy 1 txn

Insider Bitterman Robert J

Role Chairman, Pres. & CEO

Bought 10,000 shs ($11K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, $.0001 par value F1	10,000	$1.06	$11K

Holdings After Transaction: Common Stock, $.0001 par value — 431,421 shares (Direct)

Footnotes (1)

1. F1. Includes shares of common stock underlying unvested restricted stock units.

Key Figures

Shares purchased: 10,000 shares Purchase price: $1.06 per share Shares owned after transaction: 431,421 shares

3 metrics

Shares purchased 10,000 shares Non-derivative common stock purchase on August 18, 2026

Purchase price $1.06 per share Price for the 10,000-share common stock purchase

Shares owned after transaction 431,421 shares Direct holdings after the purchase, including unvested RSU underlying shares

Key Terms

restricted stock units

1 terms

restricted stock units financial

"Includes shares of common stock underlying unvested restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PHIO report for Robert J. Bitterman?

Robert J. Bitterman reported buying 10,000 PHIO common shares on August 18, 2026. The purchase was a non-derivative open-market or private transaction and increased his direct holdings, including shares underlying unvested restricted stock units.

How many PHIO shares does Robert J. Bitterman own after this transaction?

After the reported transaction, Robert J. Bitterman directly holds 431,421 PHIO shares. This figure includes shares underlying unvested restricted stock units, as noted in the filing’s footnote attached to the post-transaction holdings.

At what price did the PHIO CEO buy his shares on August 18, 2026?

The PHIO CEO bought the 10,000 common shares at a price of $1.06 per share. This per-share price is explicitly reported as the transaction price for the non-derivative open-market or private purchase.

What type of security did the PHIO Form 4 transaction involve?

The transaction involved Phio Pharmaceuticals Corp. common stock with a par value of $0.0001 per share. The filing identifies it as non-derivative common stock, not options or other derivative securities.

Does Robert J. Bitterman’s PHIO holding include unvested restricted stock units?

Yes. The reported post-transaction total of 431,421 PHIO shares includes shares underlying unvested restricted stock units. This detail is specified in a footnote tied to the post-transaction holdings figure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/19/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bitterman Robert J

(Last) (First) (Middle)

C/O PHIO PHARMACEUTICALS CORP.

411 SWEDELAND RD., STE 23-1080

(Street)

KING OF PRUSSIA PENNSYLVANIA 01581

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Phio Pharmaceuticals Corp. [ PHIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman, Pres. & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.0001 par value	08/18/2026		P		10,000	A	$1.06	431,421(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes shares of common stock underlying unvested restricted stock units.

	/s/ Lisa C. Carson, Attorney-in-fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)